アルドース還元酵素阻害剤（エパルレスタット）の尿中ケトン体検査への干渉とその機序の解明

DOI
  • 林 昭夫
    小野薬品工業 (株) 水無瀬研究所内試薬部試薬研究室
  • 谷口 健
    小野薬品工業 (株) 水無瀬研究所内試薬部試薬研究室
  • 沢田 正文
    小野薬品工業 (株) 水無瀬研究所試薬部試薬研究室
  • 杉山 正康
    小野薬品工業 (株) 水無瀬研究所内試薬部試薬研究室
  • 菅野 剛史
    浜松医科大学臨床検査医学

書誌事項

タイトル別名
  • False Positive interactions of an Aldose Reductase Inhibitor (Epalrestat) in Urinary Ketone Body and Leukocyte Tests and the Mechanisms of these Interactions.

この論文をさがす

抄録

We investigated false positive interactions of an aldose reductase inhibitor (Epalrestat) in the urinary ketone body and leukocyte tests, and investigated the mechanisms of these interactions. Four healthy volunteers were administered 50 mg of Epalrestat (M0) three times per day. Urine was collected before and after drug administration. False positive interactions were observed in the urinary ketone body and leukocyte tests. Similar results were obtained with the addition of M0, mono, and di-hydroxy derivatives, and a conjugated type of di-hydroxy derivative. Maximum absorption spectra of these derivatives (400 nm) were completely shifted to 500 nm under alkaline pH conditions. These shifts of spectra caused false positive results in the urinary ketone body test. Furthermore, these derivatives reacted with the diazo-compounds contained in the leukocyte test. Interaction with ketone bodies was confirmed by the boiling test and by the addition of iodoacetic acid to the urinary test strip. The ketone body test is mainly used for the diagnosis of the diabetic ketoacidosis. Thus, the possibility of false positive results with this agent in diabetic patients must be considered.

収録刊行物

  • 糖尿病

    糖尿病 35 (10), 819-824, 1992

    一般社団法人 日本糖尿病学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ